학술논문

Posterior reversible encephalopathy syndrome (PRES) and myeloma
Document Type
article
Source
Leukemia Research Reports, Vol 21, Iss , Pp 100407- (2024)
Subject
Myeloma
Neurotoxicity
Cerebrovascular complication
Posterior reversible encephalopathy syndrome
Chemotherapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Language
English
ISSN
2213-0489
Abstract
Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence.